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ABSTRACT 
Identifying molecular drivers of pathology provides potential therapeutic targets.   Differentiating between 
drivers and coincidental molecular alterations presents a major challenge.  Variation unrelated to pathology 
further complicates transcriptomic, proteomic and metabolomic studies which measure large numbers of 
individual molecules.  To overcome these challenges towards the goal of determining drivers of Huntington’s 
Disease (HD), we generated an allelic series of HD knock-in mice with graded levels of phenotypic severity for 
comparison with molecular alterations.  RNA sequencing analysis of this series reveals high numbers of 
transcripts with level alterations that do not correlate with phenotypic severity.  These discorrelated molecular 
changes are unlikely to be drivers of pathology allowing an exclusion-based strategy to provide a short list of 
driver candidates.  Further analysis of the data shows that a majority of transcript level changes in HD knock-in 
mice  involve alteration of the rate of mRNA processing and/or degradation rather than solely being due to 
alteration of transcription rate.   The overall strategy described can be applied to assess the influence of any 
molecular change on pathology for diseases where different mutations cause graded phenotypic severity.   
INTRODUCTION 
Identification of remediable pathological molecular processes is a cornerstone of rational therapeutic design.   A 
common first step in this strategy is to search for bio-molecules with levels that differ between normal and 
pathological states.   Powerful techniques involving genomics, proteomics, transcriptomics and metabolomics 
provide means of simultaneously identifying and reporting the concentrations of thousands of molecules.  Such 
studies reveal pathologic correlates that broadly fall into one of four classes: pathology drivers, beneficial 
responders, epiphenomenal changes, and false-positives arising from chance.   Well correlated molecular 
changes that are not pathologic drivers may be useful as state or target engagement biomarkers.  False positives 
are likely to be frequent, especially when obtained by screening large numbers of molecules.   Accumulation of 
false positive candidates makes determination of therapeutically relevant drivers, responders, and biomarkers 
difficult.   An alternate strategy to the correlative approach is to exclude candidates that fail to correlate with 
phenotypic severity.  Identification of a molecular change as not correlating with phenotypic severity argues 
against it being a driver or responder.    
This approach may be particularly useful for diseases such as Huntington’s Disease (HD) that exhibit different 
intensities of a single pathologic etiology (1).  Caused by inheritance of an expanded CAG/polyglutamine repeat 
in the Huntingtin gene, this midlife onset neurological disease exhibits wide variation in age of onset. Longer 
repeat lengths are associated with earlier onset of clinical features (2).  Murine genetic models of HD share this 
relationship between length and phenotypic onset with the exception of some extremely long transgenic CAG 
repeat mice (3-5).     
These models have been used to identify molecular alterations that might drive HD-like abnormalities with the 
goal of uncovering therapeutic targets (6-8).  Transcript profiling, for example, revealed several alterations that 
are also present in HD patient tissues postmortem (9).  These results and the presence of polyglutamine repeats 
in many other proteins involved in transcription support the hypothesis that the HD mutation acts through 
transcriptional dysregulation (10).  A speculative extension of this idea is that some transcript level changes 
drive the pathology of HD and therapies aimed at normalizing these levels might prove therapeutic.  Despite the 
promise of such potential drivers, the field is faced with the challenge of having too many such candidates.  In 
fact, approximately one third of all transcripts analyzed are found to have altered levels in HD (11).   Enhanced 
screening methods are needed to narrow this large field of candidates. 
We describe an allelic series of knock-in HD mice that allows rank ordering by phenotypic severity and 
comparison to transcript profiles from RNA sequencing analysis of four critical members of the series.  The 
mRNA studied was from the area of the brain most severely affected in HD, the striatum.  Data were analyzed to 
assess the power of the method.  Correlating transcript levels with phenotypic severity provided at least seven 
fold enrichment of driver /responder/biomarker candidates than would be expected by the standard method of 
repeatedly comparing one line to a control.  Genes with transcript levels alterations that do not correlate with 
phenotypic severity were at least 20 fold more numerous than those correlating.  The nature of the changes was 
explored by analysis of transcripts with more than one distinguishable isoform which showed that most 
transcript level alterations involve more than just changes in transcription rate.  This result implicates the HD 
mutation in alterations of mRNA processing and/or degradation.    
 
RESULTS 
The HD Knock-in Allelic Series 
We previously reported a mouse model of HD where gene targeting was used to replace the short CAG repeat of 
the mouse HD gene with 150 CAGs (12).  This mouse exhibited mild late onset motor, behavioral, and 
neuroanatomic abnormalities consistent with HD (12, 13).   A line congenic to C57BL/6 was derived; then germ 
line instability in repeat number was exploited to selectively breed longer and shorter repeat variants.  The 
resulting lines with 50, 100, 150, 200, 250 and 315 CAGs were maintained (Fig. 1A).  HD knock-in mice with 
fewer than 100 CAGs show no overt HD-like abnormalities, 150 CAGs mild symptoms (12) while longer 
repeats (200 to 250) show earlier ages of onset of the same abnormalities (14, 15).   .    
Reduction in HD mRNA Levels with Increased Repeat Size  
Longer repeat alleles have lower HD mRNA levels (Fig. 1B) and express expanded polyglutamine HD protein 
at levels readily detectable by western analysis (Fig. 1C).  Reduction in HD mRNA levels with increasing CAG 
repeat length is a property shared by the longer repeat length versions of an analogous allelic series derived from 
the R6/2 transgenic line of mice (Fig. 2).  The R6/2 series  was created by random insertion of a portion of the 
human genomic region containing the promoter and exon 1 of HD with an expanded repeat (16) and breeding of 
germline repeat size changes to create a series of different repeat lengths each with the same albeit unknown 
genomic location (5).   
The expression decrease in longer length repeats might explain the diminishing phenotypic abnormalities seen in 
the R6/2 series with repeats above ~300 CAGs in length (3-5).  These data are consistent with the view that 
longer repeats produce a more toxic gene product on a per molecule basis but reduced transgene expression of 
super long repeat lengths diminishes phenotypic effects (3-5).   
HD-like abnormalities in the HDQ315/+ line 
Previous studies on the R6/2 allelic series show decrements in HD-like abnormalities for mice with around 300 
CAGs when compared to 150 CAGs (3-5, 17).  Unlike the R6/2 series, our knock-in series does not share the 
reduction in phenotype shown in the transgenic R6/2 series at 300 repeats.  The toxicity of the HDQ315 allele is 
significantly greater than HDQ150 and HDQ200 as suggested by inability to breed HDQ315 allele homozygotes 
(Table 1).    Longitudinal behavioral analyses of the HDQ315/+ line show deficits as early as 30 weeks which 
worsen in degree through 65 weeks (Fig. 3).    Neuroanatomic analyses show a decrease in D1 and D2 dopamine 
receptor binding by 35 weeks of age and a significant decrease in brain weight at 70 weeks, not accompanied by 
striatal neuronal loss (Fig. 4).  Striatal aggregates immunoreactive to N-terminal HD antibodies were also 
prevalent at 70 weeks (Fig. 4).   
Ordering by Phenotypic Severity 
These behavioral and neurochemical analyses place the age of onset of mice heterozygous for the HDQ315 
allele and the wild-type allele (HDQ315/+) somewhere between the later onset HDQ150/150 and the earlier 
onset HDQ200/200 lines.  This rank ordering is illustrated in Fig. 5 which compares body weight loss, rotarod 
performance and general activity levels for the three lines.  Comparison with other data supports this ordering.  
Between 35 and 40 weeks of age, HDQ315/+ mice show D1 dopamine receptor binding reduced by 25-30% 
compared to WT, midway between HDQ150/150 mice (11% reduction) and HDQ200/200 mice (50-60% 
reduction) (13).  The utility of ranking a heterozygote between two homozygotes is that it results in different 
orders for phenotypic severity (WT < HDQ150/150 < HDQ315/+ < HDQ200/200) and mutant gene dosage (WT 
< HDQ315/+ < HDQ150/150 and HDQ200/200).  Differential ordering dissociates molecular changes more 
influenced by expression levels of mutant Huntingtin from molecular changes related to the overall toxicity of 
the mutation.   
Rationale for Molecular Comparisons within the Series 
The comparison of molecular levels typically involves finding differences between two groups (e.g. mutant vs. 
WT control).  In the HD field, where several animal models are available, consensus as to the validity of a 
changed molecular level is formed by the compilation of varied mutant vs. WT comparisons.  This approach is 
based on the assumption that molecular drivers of each mutant’s abnormalities are the same.  This assumption is 
also important for the approach described here in which molecular levels are compared simultaneously across 
several lines.   There is support for the view that the drivers in the HD knock-in allelic series are similar.  First, 
the mutation is the same except for repeat length.  Second, use of congenics reduces genetic background effects.  
Third and most important, the abnormalities seen are strikingly similar but with different ages of onset 
suggesting longer repeat lengths accelerate the same toxic processes.  Phenotypic similarity also holds true when 
a specific repeat length is made homozygous.  Both HDQ150 and HDQ200 allele homozygotes exhibit 
strikingly similar behavioral and neuroanatomic features which present at an earlier age than their corresponding 
heterozygous lines (12-14, 18).  The HDQ315/+ mice share this similarity in type of abnormality (Figs. 3-5).  
Further supporting comparisons between homozygous and heterozygous lines is evidence that loss of wild type 
HD in homozygotes has little effect on striatal transcript profiles.   Ninety four percent concordance is seen 
between transcript level alterations HDQ150/150 (which lack WT HD) and R6/2-Q150 mice (which have wild 
type endogenous HD) (9).   These genetic and phenotypic similarities support the approach of simultaneous 
comparisons across the allelic series. 
Screen for Expression Correlates and Discorrelates 
RNA-sequencing analysis was used to assess early changes in striatal transcript levels between WT, 
HDQ150/150, HDQ315/+ and HDQ200/200 lines.   We chose 21 weeks of age given results that some early 
markers of HD show significantly altered transcript levels at this age and since it was an age early in the course 
of disease.  At this age, stereological results (13, 14, Fig. 4) show no decrease in striatal neuronal number, 
eliminating skewing of transcript levels secondary to neurodegeneration.  The depth of sequencing allowed 
analyses of transcript levels from 15,543 genes based on the inclusion criteria presented in Materials and 
Methods.   Table 2 shows that the number of transcript levels changing in the same direction vs. WT for 
HDQ150/150, HDQ315/+ and HDQ200/200 mice allowing for different levels of variation.   This table shows 
that a transcript level alteration in one direction vs. wild type for all three mutants were at least 14 fold more 
than expected if the changes were independent in each line.  Such concordance supports a multiple comparison 
approach for transcript profiling.   
Graphical examples of transcript levels across the series are presented in Fig. 6.  The relationships of transcript 
levels across the series are classified as described in Materials and Methods.  Panels A-C show a class termed 
“Step-wise correlates” which represent driver/responder/biomarker candidates.  Panels D-F show a new class 
that is not possible to identify for individual mutant vs. WT comparison studies.  This class is termed 
“discorrelate” because it indicates there can be no correlation between transcript level and phenotypic severity.   
It arises when two or more of the members of the series show a trend which is then broken by one or both other 
members of the series.   As such, the discorrelate class consists of transcripts with a high probability of being 
negative when addressing the hypothesis that a transcript level alteration is driving phenotype.   A look at the 
discorrelate class reveals a shortcoming in a single mutant vs. WT analysis that the simultaneous assessment of 
the several lines of the allelic series overcomes.  For example, Fig. 6E shows that an experiment assessing Tbr1 
mRNA levels in the single HDQ150/150 vs. WT comparison would show a large increase with the HD mutation 
while an experiment that compared HDQ315/+ vs. WT would show no change.  The great number of such 
discorrelates suggests single mutant vs. WT comparisons often lead to false positive driver candidates. The 
potential power to rule out false positives using multiple line comparisons with an ordered grading of 
phenotypic severity as opposed to treating them as three independent mutant vs. WT comparisons is shown in 
Table 2.   These data show that the multiple comparison approach was at least 7 times better at ruling out false 
driver/responder/biomarker candidates.  Furthermore, in Table 3, a complete list of mRNAs where such 
classifications have statistical support, discorrelates vastly outnumber step-wise correlates.  A wider view of 
phenotypic classes is presented in Table 4.  In this table every gene’s total mRNA level is classified without 
regard to statistical significance by allowing different levels of variation.   These data reveal that step-wise 
phenotypic correlates, an indicator of a potential driver/responder/biomarker of pathology, are rare, at least 20 
fold fewer were found than discorrelates.   Partial correlates, a less stringent classification allowing for some 
equivalent values, are also typically less prevalent than phenotypic discorrelates.  For transcripts with altered 
levels, phenotypic discorrelates are the largest class, representing thousands of genes.    
Graphical examples of transcript levels with respect to mutant gene dosage are shown in Fig. 6 (panels G-L).   
Gene dosage ordering provides similar distribution among classes as ordering by phenotypic severity (Table 4).  
The high numbers of partial correlates for a gene dosage ordering suggests that some mRNA level alterations 
are more influenced by the concentration of mutant HD gene product than by the toxicity of longer repeat 
lengths.    
We also used QRTPCR to examine three molecular markers for HD commonly used in mouse models. The gene 
products for cannabinoid receptor 1 (Cnr1), the dopamine receptor D2 (Drd-2), and the protein phosphatase 1 
regulatory subunit 1B (Darpp32) were shown to be lowered in HD mice prior to the onset of motor and 
behavioral abnormalities (18-20)  Consistent with prior studies, transcript level reductions compared to wild 
type were shown for all mice with repeat lengths above 150 CAGs (Fig. 7).  Each marker has a similar mRNA 
level profile across the allelic series with WT having high levels of marker mRNA and HDQ200/200 having the 
least.  Each also has a statistically significant spike for HDQ315/+ indicating their mRNA levels discorrelated 
with phenotypic severity.  Thus the degree of these marker mRNA reductions at 20 weeks is not a predictor of 
age of onset which has implications for therapeutic strategies designed to normalize their expression levels.  
This analysis shows the advantage of the use of an allelic series in assessing the contribution of specific 
molecular alterations to pathology.   
Expanded Repeat HD mutations Effect Processing and/or Degradation Rather Than Transcription Alone 
Three factors dictate mRNA levels:  transcription, processing (e.g. splicing) and degradation rates.  The ability 
of RNA sequencing to differentiate between isoforms from a single promoter provides a means of assessing the 
hypothesis that most transcript levels are altered by changing transcription rather than processing or degradation.   
This is achieved by considering all genes with more than one isoform transcribed from a single promoter.    At 
steady-state these factors are related to each other by the following equation:  KT*Pi=KD*FPKMi where KT is 
the rate of production of full length primary transcript in FPKM produced per sec, Pi is the proportion of the 
mRNA that is processed to that particular isoform, KD is the rate of degradation per second and FPKMi is the 
measured level of the specified particular isoform.  For the major isoform (defined as the isoform with the 
highest FPKM from its promoter in the WT line) the equation becomes KT*Pmajor=KD,major*FPKMmajor.  For 
all other isoforms from the same promoter, minor isoforms, the equation becomes 
KT*Pminor=KD,minor*FPKMminor.  Dividing the two equations leads to the following relation 
FPKMminor/FPKMmajor = (KD,major *Pminor)/(KD,minor*Pmajor) a ratio we term the P/D ratio because it is 
dependent only on processing and degradation and independent of the rate of transcription from that promoter.   
Equivalent P/D ratios for any gene’s transcripts between lines might be achieved if there is a change only in 
transcription rate or if expanded CAG repeats effect degradation and or processing rates equally for the 
compared isoforms.  Both scenarios leading to equivalent P/D ratios are easily imagined.  In contrast, a change 
in P/D ratio for the same transcript in two mouse lines indicates one or more of the factors KD,major, Pminor, 
KD,minor, Pmajor  is altered between lines.   Thus different P/D ratios for a transcript in different mouse lines 
indicate expanded CAG repeats influence processing and/or degradation rates.  P/D ratios were calculated for 
7434 minor transcripts from 5950 genes.     Table 5 shows the proportion of transcripts changed in level where 
P/D ratios also change across a range of allowed variances.  A majority of isoforms from genes changed in 
transcript level between lines show alteration in P/D ratio between WT and each mutant studied.  Therefore, 
expanded CAG repeats usually alter transcript levels with involvement of processing and/or degradation rates 
rather than transcription rate alone.     
DISSCUSSION 
The analysis of trends across an allelic series reveals several molecular features that are difficult or impossible 
to determine by multiple mutant vs. wild type comparisons.  One feature is the lessening of HD mRNA levels 
with longer repeats.  This effect is also seen for very long CAG repeats in the R6/2 transgene (3-5).  Our 
analysis shown in Fig. 2 revealed an unexpected feature of the R6 series.  The R6/2Q50 brain transgene mRNA 
level is 3 fold less than for the R6/2Q110 line.  There are several potential explanations for this result.  One is 
that the extra 60 CAGs provide greater stability for the R6/2Q110 transgene mRNA.  This does not seem to be 
the case for the full-length mRNAs from the endogenous locus, as shown in Fig. 2B, where the brain knock-in 
HDQ50 mRNA is greater in level than that of the HDQ100.  Alternatively, the location of the transgene might 
interact with repeat length allowing for an increase of transcription rate by the addition of 60 CAGs.   One 
potential molecular explanation for this scenario is that site of transgene insertion (which is the same for both 
R6/2Q50 and R6/2Q110) might be in a relatively closed chromatin configuration at 50 CAGs compared to 110 
CAGs.  This feature is not shared by the endogenous locus suggesting a different potential for transcription at 
the R6/2 location vs. endogenous HD.   
The allelic series also provides a more powerful means of screening potential driver/responder/biomarker 
candidates than standard mutant vs. wild type analyses.  Enhanced screening methods are needed given the 
thousands of transcript level alterations associated with HD (21).   There are practical considerations to be taken 
into account when using an allelic series for such a screen.  First, given the present cost of RNA sequencing, the 
addition of several additional lines to make up the series may limit the number of biological replicates that can 
be performed for an initial screen.   This shortcoming is partially compensated by each mutant line in the series 
being a graded replicate.   The strategy of using a low cost screen with few biological replicates to identify 
candidate transcripts should be followed by confirmation with a large numbers of biological replicates.  Fig. 7 
shows the use of 9-12 biological replicates for each line in the series using QRTPCR to determine striatal levels 
of Drd-2, Darpp32 and Cnr1 mRNAs.   A second consideration is whether heterozygous and homozygous lines 
should be compared as members of the same series.  Heterozygotes have a single gene dose of an expanded 
repeat allele and a dose of the wild type allele.  Homozygotes on the other hand have two gene doses of the 
expanded allele and no wild type.   These genetic differences might influence transcript profiles in a series that 
mixes heterozygous and homozygous members.   In this initial study we chose members solely based on their 
phenotypic severity.  The comparison HDQ315/+ heterozygotes (one mutant, one wild type dose) to wild type 
(zero mutant, two wild type gene doses) to the homozygous HDQ150/150 and HDQ200/200 lines (two mutant, 
zero wild type gene doses) was used here to show that gene dosage correlates better than phenotypic severity 
with the levels of some transcripts (Table 4 and Fig. 6 G-I).   The presence of the wild type allele or gene dosage 
of the mutant allele might also be responsible for the HDQ315/+ line breaking the downward trend for Drd-2, 
Darpp32 and Cnr1 mRNAs levels shown in Fig. 7.   The validity of comparison between heterozygous and 
homozygous series members is strengthened by a previous study showing 94% concordance between transcript 
level alterations in HDQ150/150 mice (which lack WT HD) and R6/2-Q150 mice (which have wild type 
endogenous HD) (9) and the qualitative similarity of the HD-like phenotypes seen in heterozygous and 
homozygous members of this series.   A third practical consideration is the determination of which tissue should 
be used for RNA sequence analysis.  In the case of HD several brain regions are known to be affected by the 
expanded repeat mutation (1).  In this initial study we have chosen to determine the effects of the HD repeat 
mutation on striatal mRNAs, since it is considered to be the most affected brain region in HD.  The analyses of 
other brain regions and integration of results with those of the striatum will be needed to provide a more 
complete picture of the effects of expanded repeat mutations in these HD mouse models.   
There are numerous plausible theories as to the nature of differentially expressed genes associated with disease 
states.  A change in any particular transcript’s level might be a downstream effect coincident with but not 
causally related to pathology.  Reproducible members of this class might serve as valuable biomarkers of 
pathology but not as candidates for therapeutic intervention.  Alternately, a transcript’s level change may be a 
protective response to the genetic insult of the expanded repeat in HD.  Finally, a transcript’s level change might 
be responsible for some or all of the pathology.  Such drivers and protective responders might then be altered in 
level for therapeutic purposes.  There are several potential pitfalls in the path towards a complete classification 
of transcript levels in HD.  The allelic series provides a means of eliminating some of the major experimental 
pitfalls, most importantly the elimination of false positives caused by normal variation in experiments which 
assess large numbers of transcripts simultaneously.  The allelic series also provides a means of differentiating 
those candidates where degree of transcript level alteration follows degree of phenotypic severity (step-wise 
correlates) from those that might be subject to threshold effects (partial correlates).   
Previous transcript profiling of HD mouse models and postmortem tissues from HD patients has provided lists 
of genes with consistent expression changes in HD.  We took one such list (Table 3 of (21)) and found, of the 
149 listed mRNAs, 100 genes met the criteria for inclusion in our RNA-sequencing analysis.  Table 6 shows an 
overview of these HD related gene expression changes.  Surprisingly there are several discorrelates amongst the 
HD related transcripts.  This discrepancy may be due to methodological differences given previous studies relied 
on HD vs normal RNAs assessed with chip hybridization methods.  Overall, however, selecting these HD 
related candidates enriches the correlate class at the expense of discorrelates showing a concordance with this 
and previous studies.     
Despite this concordance, literature searches with our best driver/responder/biomarker candidates fail to show 
any previously published work on these genes with regard to HD.  As such the seven statistically supported 
phenotypic correlates presented in Table 3 represent new potential biomarkers or therapeutic targets.  There is 
one neurotransmitter receptor, the mu-type opioid receptor (Oprm1), which is pharmacologically tractable (22).  
One has antioxidant function, the extracellular superoxide dismutase [Cu-Zn] (Sod3) whose activity might be 
replaced by chemical free-radical scavengers (23).  One is involved in neuroprotection, the insulin-like growth 
factor binding protein 2 (Igfpb2) (24) and the other four are involved in hemoglobin production.  Hbb-bs and 
Hbb-b1 code for hemoglobin beta chains while Hbb-a1 codes the alpha chain.   Alas2 codes for the first step in 
the heme biosynthetic pathway.   Although classically considered erythroid specific, expression of hemoglobin 
has been shown to occur in rodent striatal neurons isolated by laser-capture microdissection (25).  Blood 
contamination in our experiment was ruled out by assessing the levels of other blood mRNAs Rhag, Spta1 and 
Epb4.2 which were either absent or at least 6 fold below our lowest FPKM threshold for inclusion in this study 
(FPKM < 0.052).   Although these seven candidates might be molecular drivers of HD pathology, they might 
also be responding to the presence of the HD mutation in either a beneficial or neutral manner.    
Despite the advantages of the allelic series, its use to provide positive correlative results, as most studies do, 
would be subject to the logical problems of traditional inductivist methods of scientific inquiry (26).  The new 
discorrelate class, however, provides a means of interpretation that does not rely on induction, rather 
falsification of the hypothesis that the expression level of a gene drives a pathological process.  A discorrelate 
under any one set of conditions despite correlation under many other conditions argues against that change being 
a sole driver of pathology.   More complex hypotheses involving threshold expression levels sufficient to cause 
pathology and combinations of expression alterations of groups of genes would also be falsifiable.   
By seeking discorrelates, the potential for eliminating false positives becomes additive between different 
laboratory environments and conditions.  The number of different conditions that might be applied to reveal 
discorelates is already quite large given the many attempted treatment regimens that have little effect on 
pathological severity.  Such treatments may reveal further discorrelates by having disparate effects on gene 
expression levels.     
The identification of pathological discorrelates is a particularly attractive approach to eliminating pathologically 
neutral alterations leaving a short list of potential drivers of pathology when one considers there are a finite 
number of processes, metabolites, proteins or in this case transcripts in human and mouse tissues.  For example, 
the number of protein coding mRNAs in the entire mouse genome is estimated to be around 30,000 (27).  Since 
these can now be queried en-mass, analysis of the entire transcriptome to reveal a complete short list of 
therapeutically relevant changes is within reach.  The addition of the simultaneous assessment of several 
members of an allelic series adds the power of enhanced discrimination to this approach.  This work represents a 
first step of its type towards ultimately saturating the transcriptome to determine which, if any, are 
therapeutically relevant molecular alterations.  This approach is applicable to any measurable molecular level or 
process for any disease where a graded pathology exists or can be experimentally produced.     
MATERIALS AND METHODS 
Generation of Allelic series 
The original HD knock-in line (12) was backcrossed to C57BL/6J mice for 10 generations to establish congenic 
lines containing the expanded repeat mutation.   Germline instability of the CAG repeat number was exploited to 
choose longer and shorter CAG repeat lengths for breeding of individual lines with different repeat lengths.  To 
confirm that the lines used in this study were congenic to C57BL/6J we analyzed our RNA sequencing results 
by alignment to the C57BL/6J genome (mm10 from UCSC) using the aligner STAR (version 2.5.0b) in 2-pass 
mapping mode.  Variants were called using GATK (version 3.5) following their Best Practices 
Guide.  Sequences that differed from C57BL/6J were considered candidates for comparisons between each 
mutant and the wild type line.  These candidates were well dispersed throughout the mouse genome representing 
every chromosome with an average distance between candidates of 1.2 million bases.   The HDQ200/200 line 
had 2 of 403 candidates with sequences differing from the WT line.   The HDQ150/150 line had 1 of 359 and 
the HDQ315/+ line had 0 sequence differences of 392 candidates.   This analysis shows greater than 99.5% 
sequence identity between the C57BL/6J wild type line and each mutant line as well as only 3 sequence 
variations between mutants and C57BL/6J wild type controls in over 25 million bases sequenced per line.  These 
results are consistent with all mutant lines being congenic to C57BL/6J.  
Motor and Behavioral Assessment  
Groups of 32 HDQ315/+ (16 male, 16 female) and 26 WT (15 male, 11 female) were longitudinally assessed at 
10, 20, 30, 40, 50 and 65 weeks of age.   No major differences were seen between males and females for the 
tests shown so their data was combined.  Rotarod analysis was performed once a day for 3 training days 
followed by 5 days of testing on a gradually accelerating Ugo Basile 7650 from (4-40 RPMs during first 5 min 
of a 10 min trial).  Starting at 30 weeks of age mice were tested in a Bioseb Automatic foot misplacement 
apparatus (EB-Instruments, Tampa, FL). Mice walked on a 79 cm horizontal ladder (1 rung/cm) through a lit 
corridor (50 mm wide with opaque walls) to a shaded area and the number of missteps and time to traverse 
ladder was averaged over three trials.  In cage activity was determined as we previously described (28) with 24 
hours of acclimation followed by 3 days and nights of data acquisition which was averaged for each mouse.  
Open field test was performed as previously described (28) in a 50 X 50 cm square arena with walls and floor 
made of plexiglass.  Distance traveled and position during 4 minute trials was determined by computerized 
video recording and the Ethovision 3.1 software (Noldus Information Technology, Wageningen, Netherlands).  
The voluntary wheel cage (Lafayette Neuroscience, Lafayette, IN) was used according to manufacturer’s 
instructions with one day of acclimation was followed by 3 days and nights of data acquisition which was 
averaged for each individual mouse.  Grip strength was measured as previously described by us (28) using a 
Chatillon grip strength meter (Wagner Instruments, Greenwich, CT).  All procedures were conducted in 
compliance with the Guide for the Care and Use of Laboratory Animals as adopted by the NIH and approved by 
the Institutional Animal Care and Use Committee of the University of Alabama at Birmingham.   
Neuroanatomical Analyses  
Receptor binding autoradiography for D1 and D2 dopamine receptors was performed as we previously described 
(14).  Immunocytochemistry to detect HD aggregates was performed on three 70 week old HDQ315/+ mice and 
an age matched wild type control.  Brains fixed overnight in 4% paraformaldehyde were cryoprotected and 
stored at -80 oC; 30m coronal sections were cut using a freezing, sliding microtome. Sections were stained 
using the HD N-18 primary antibody (8767, Santa Cruz Biotechnology, Santa Cruz, CA) and a Cy3 conjugated 
anti-goat IgG antibody (705-165-003, Jackson ImmunoResearch, West Grove, PA).   The stained sections of the 
striatum were digitized using an Olympus DP73 camera, and images were taken using Olympus fluorescence 
microscope with 552-565 nm filter (WIG cube) for Cy3-antibody detection.  An inverted grayscale image of 
antibody fluorescence was created using Adobe Photoshop software for Fig. 4G and 4H.  Stereology was 
performed as in (Kumar et al., 2012).   
Analyses of DNA, mRNA and Protein  
Genotyping was performed by PCR across the repeats using reactions with final concentrations indicated: 
10ng/ul each primers CCCATTCATTGCCTTGCTG and GCGGCTGAGGGGGTTGA, 2M betaine, 400uM 
dNTPs, 15 mM TrisHCl pH 8.9, 8 mM Ammonium Sulfate, 75 ug/ml BSA, 1.25 mM MgCl and 0.5 mM beta-
mercaptoethanol and 2.0 ng/ul tail biopsy DNA and 0.04U/ul LA Taq (TaKaRa).  Reactions were carried by 
incubating 94o C 5 min, then 30 cycles of  94o C 30 sec, 53o C 30 seconds, 72o C 3 minutes and following 
cycling 72o C 5 minutes.  PCR products were analyzed by running on long 1% agarose gels, stained with 
ethidium bromide and visualized with UV light.  All samples were compared to standards sized independently 
by Laragen, Inc (Los Angeles, California) and mice greater than 15 CAGs from target length were excluded.   
R6 mice were genotyped by Laragen.   Allele specific HD QRTPCR was previously described by us in (15). 
RNA preparation was performed as previously described (29). cDNA for QRTPCR was made using 200 ng of 
sample RNA by the Applied Biosystems Reverse Transcription kit according to manufacturer instructions (Life 
Technologies, Grand Island, NY).  Assays for markers used pre-made Taqman primers and probes and 
mastermix from Appliedbiosystems Cnr1 (Mm01212171), Drd-2 (Mm00438545), DARPP32 (Mm00454892) 
and mouse -actin control (4352341E).  HD QRTPCR was as previously described (29).  R6 transgene mRNA 
levels were determined by QRTPCR as we previously described (30) on RNA extracted from single 
hemispheres of brain at 6 weeks of age. All QRTPCR assays were performed in an ABI Prism 7900HT (Life 
Technologies, Grand Island, NY).  Groups included from 9-12 mice aged 24 +/- 4 weeks.  Western analysis was 
performed as previously described (30) but with 4-8% gradient polyacrylamide gels using primary antibodies 
against HD (MAB2166, Millipore, Darmstadt, Germany), polyglutamine (MAB1574, Millipore) and -tubulin 
(T5168, Sigma, St Louis, MO).   
For RNA sequencing analysis striatal mRNA samples of each genotype were pooled such that each mouse 
contributed equal amounts of total RNA to one of the four different groups: 1) WT n= 12 age 21.7+/- 0.1 weeks, 
2) HDQ150/150 n=6 age 20.2+/-0.1 weeks, 3) HDQ315/+ n=8 age 21.1+/-0.6 weeks  and HDQ200/200 n=10 
age 21.1+/-0.6 weeks .  Each group had an equal number of males and females.  RNA quality was confirmed 
using the Agilent 2100 Bioanalyzer according to manufacturer instructions followed by 2 rounds of mRNA 
purification using oligo dT magnetic beads and cDNA synthesis using SureSelect Strand-specific RNA Library 
generation kit (Agilent, Santa Clara, CA).  cDNA production included fragmentation, repair of ends, A-tailing 
and the ligation of separate barcode identifiers for each of the four samples. cDNA libraries were quantitated 
using qPCR in a Roche Lightcycler 480 with a kit for library quantitation (Kapa Biosystems, Woburn, MA). 
Paired end 2X50bp sequencing runs were performed in the Illumina HiSeq2500.  Sequence data was converted 
to FASTQ Sanger format using Illumina’s bcl2fastq version 1.8.4 and aligned to the University of California, 
Santa Cruz mouse mm10 genome using TopHat version 2.0.11 and the short read aligner Bowtie version 2.1.0.  
Cufflinks version 2.1.1. was used to assemble transcripts and estimate abundances. Cuffdiff was used to find 
significant changes in transcript level for all six possible pairwise comparisons of the four samples (shown in 
Table 3).   
Further refinement of the data was carried out in Excel spreadsheets.  A lower cutoff for FPKM values of 0.3334 
was established using Cuffdiff readouts by determining the minimum FPKM value that provided a status of OK 
(rather than NOTEST) when compared to a zero FPKM value for each of the six pairwise comparisons and 
averaging the six.  To insure 5’ ends were represented fully we defined 103 groups based on length of transcript 
and plotted the average counts of each group against median length of each group.  In theory longer transcripts 
should have more counts, however, we found a plateau starting after 4186 bp.  Visual inspection of number of 
reads on longer transcripts confirm a large drop off in reads more than ~4Kb from the polyA tail.  Since half of 
the mice used were female, we also excluded Y-chromosome encoded genes.  Furthermore, since small changes 
in mitochondrial number between lines might have a dramatic effect on transcript levels of mitochondrial 
encoded genes, we limited our analyses to nuclear-encoded genes.   Thus we only include transcripts based on 
the following inclusion criteria: 1) maximum transcript length for a gene is less than 4186 bp, 2) at least one 
FPKM value for any comparison is greater than 0.3334, 3) gene is nuclear encoded and 4) gene is not on the Y-
chromosome.   
Definitions of Classes   
For data in Tables 2, 4, 5 and 6 Excel spreadsheets were designed to determine relationships between a 
transcript in different lines allowing for variation  which can be set arbitrarily as a percentage of FPKM value.  
FPKM values for a transcript in two lines were considered changed when the smaller FPKM+ did not overlap 
with the larger FPKM-.   Comparisons across the series were then made leading to the following classes for 
ordering by phenotypic severity (WT < HDQ150/150 < HDQ315/+ < HDQ 200/200).   The “No effect” class 
exhibits no change in levels across the series having FPKM values described as  
WT +/-  = 150 +/-  = 315 +/-  = 200 +/-  
Where WT represents Wild Type FPKM, 150 represents HDQ150/150 FPKM, 315 represents HDQ315/+ 
FPKM and 200 represents HDQ200/200 FPKM.  
The “Step-wise correlate” class exhibits mRNA levels that either decrease or increase with phenotypic severity 
having FPKM values described as  
WT +/-  > 150 +/-  > 315 +/-  > 200 +/-  OR WT +/- < 150 +/-  < 315 +/- < 200 +/-  
The “Partial correlate” class is a less stringent form of the “step-wise” class allowing for some equivalent values 
having FPKM values that are not all equal, are not “step wise” and conform to the following 
WT +/-  > 150 +/-  > 315 +/-  > 200 +/- OR WT +/- < 150 +/- < 315 +/-  < 200 +/-  
The “Discorrelate” class exhibits a clear breakage of correlation between mRNA level and phenotypic severity 
with FPKM values described as any of the following 
                          WT +/-  < 150+/-  and 150 +/-  > 315 +/-  or 200 +/-  OR 
                          WT +/-  > 150 +/-  and 150 +/-  < 315 +/-  or 200 +/-  OR 
                          WT +/-  or 150 +/-  < 315 +/-  and 315 +/-  > 200 +/-  OR 
                          WT +/-  or 150 +/-  > 315 +/-  and 315 +/-  < 200 +/-  
For ordering based on mutant gene dosage WT has 0 mutant gene doses, HDQ315/+ has one and both 
HDQ150/150 and HDQ200/200 have 2.  Thus leading to the ordering (WT < HDQ315/+ < HDQ150/150 and 
HDQ200/200) and definitions below.  The “No effect” class exhibits no change in levels across the series having 
FPKM values described as  
WT +/-  = 315 +/-  = 200 +/-  = 150 +/-  
The “Step-wise correlate” class exhibits mRNA levels that either decrease or increase with mutant gene dosage 
while 150 and 200 are equivalent allowing for reasonable experimental error having FPKM values described as  
WT +/-  > 315 +/-  > 200 +/-  and 150 +/-  and 200 +/- 6% = 150 +/- 6%   OR 
             WT +/-  < 315 +/-  < 200 +/-  and 150 +/-  and 200 +/- 6% = 150 +/- 6%. 
The “Partial correlate” class is a less stringent form of the “step-wise” class allowing for some equivalent values 
having FPKM values that are not all equal, are not “step-wise” and conform to the following: 
WT +/-  > 315 +/-  > 200 +/-  and 150 +/-  OR 
                                     WT +/-  < 315 +/-  < 200 +/-  and 150 +/-  
The “Discorrelate” class exhibits a clear breakage of correlation between mRNA level and gene dosage with 
FPKM values described as any of the following 
WT +/-  < 315 +/-  and 315 +/-  > 200 +/-  or 150 +/-  OR 
                          WT +/-  > 315 +/-  and 315 +/- < 200 +/- or 150 +/- OR  
                          WT +/- < 315 +/- and WT +/-  > 200 +/- or 150 +/- OR 
                          WT +/-  > 315 +/-  and WT +/- < 200 +/- or 150 +/-  OR 
                          WT +/- < 150 +/- and 200 +/- < WT +/- or 315 +/-  OR 
                          WT +/-  > 150 +/-  and 200 +/-  > WT +/-  or 315 +/-  OR  
                          315 +/- <150 +/-  and 200 +/-  < WT +/- or 315 +/- OR 
                          315 +/-  >150 +/-  and 200 +/- > WT +/- or 315 +/-    
Data and Mouse Line Sharing 
RNAseq data is available from NCBI’s Gene Expression Omnibus accession number GSE73743.  Mouse lines 
are available from the Jackson Laboratory, Bar Harbor, ME (Stock numbers 016521-016525 and 004595). 
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LEGENDS TO FIGURES 
Figure 1.  Molecular aspects of the HD knock-in allelic series.    (A) PCR across the repeats of genomic DNA 
from tail biopsies.   Lane 1-8 represent MW ladder, WT and heterozygotes for 50, 100, 150, 200, 250 and 315 
CAGs in the mouse HD gene respectively.  (B) Striatal HD mRNA levels of long repeat mRNAs relative to wild 
type as determined by allele specific HD QRTPCR.  Levels in homozygotes was halved to provide mRNA level 
per allele.  Each assay performed in triplicate and results normalized to -actin mRNA levels of same sample.  
White, grey and black shading indicates WT, heterozygous and homozygous for expanded allele respectively.   
Error bars indicate standard error of the mean and asterisks show level of statistical certainty vs. line ~100 
CAGs shorter as determined by ANOVA with Tukey-Kramer multiple comparisons test (*p<0.05, **p<0.01, 
***p<0.001).  Number of mice is shown at the base of each bar.  (C)  Western blot analyses of striatal protein 
from allelic series.   Lanes 1-7 represent WT, 50, 100, 150, 200 homozygotes, 250 and 315 heterozygotes 
respectively.  Top panel shows detection with the anti-polyglutamine antibody 1C2, middle shows the same blot 
after stripping and detection with the anti-HD antibody 2166 and lower with anti--tubulin antibody.  Filled 
arrowheads indicate the expected migration of wild type Huntingtin protein (345 kDa) and open arrowhead 
indicates expected migration of -tubulin (50kDa).   
Figure 2.  Transgene mRNA levels from the R6 HD allelic series.  (A) R6 transgene mRNA copies per ng of 
whole brain RNA at 6 weeks of age using a transgene specific QRTPCR assay.  All R6 mice were hemizygous 
for transgene which is inserted in the same unknown location of the genome for all lines in the series. (B) HD 
mRNA copies per ng of whole brain RNA at 6 weeks of age weeks for HDQ50 and HDQ100 knock-in 
homozygotes by QRTPCR across exon2,3 junction.   Absolute numbers of cDNAs present in each sample were 
calculated by interpolation to a standard curve of known amounts of DNA template for R6 or endogenous 
mouse HD.  Number of mice is shown at the base of each bar.  Error bars indicate standard error of the mean.  
Unless annotated asterisks reflect comparison to measures 2 bars to left (typically 100 CAGs shorter) as 
determined by ANOVA with Tukey-Kramer multiple comparisons test (*p<0.05, **p<0.01, ***p<0.001)  
acompared to all other transgenic R6 lines shown including 50s bcompared to HDQ50s. 
Figure 3.  Longitudinal evaluation of behavioral abnormalities of the HDQ315 line at different ages.  (A) 
Accelerating rotarod.  (B) Time to traverse horizontal ladder in automated foot misplacement apparatus. (C)  In 
cage activity (lower beam breaks per 24 hour period).   (D) Open field distance traveled per four minute trial.  
(E) Voluntary wheel cage distance traveled per 24 hour period.  (F) Four paw grip strength.  Open and grey bars 
represent mean of WT and HDQ315/+ mice, respectively.  Error bars indicate standard error of the mean and 
number of mice in each group shown at base of bar.  Groups contain approximately equal numbers of males and 
females.  Statistical differences between WT and HDQ315/+ groups at same age as determined by t-test shown 
above bar (*p<0.05, **p<0.01 and ***p<0.001). Statistically significant differences within the HDQ315/+ 
group between 30 week old and both 50 and 65 week old were found for all six tests shown (p<0.05 by Kruskal-
Wallis non-parametric ANOVA with Dunn’s multiple comparison test) showing progression of abnormality 
with age.  
Figure 4.  Neuroanatomic and neurochemical features of the HDQ315 line.   (A) HDQ315/+ mice have reduced 
brain weight at 70 weeks of age.     (B-D)  HDQ315/+ mice show reduction in striatal volume, increase in 
striatal neuronal density and no loss of NeuN+ striatal neurons at 70 weeks of age.  (E-F) HDQ315/+ mice show 
reductions in D1 and D2 receptor binding at 35 and 70 weeks of age.  Open bars indicate WT mice and grey 
bars HDQ315/+ mice.  Number of mice in each group is shown at base of bar. Asterisks indicate significant 
difference from wild type (* p<0.05, **p<0.01 and  ***p<0.001) by t-test.  (H) Shows aggregates 
immunoreactive to anti-HD antibody in 70 week old HDQ315/+ striatum that are not present in age matched 
WT controls (G).  Bar indicates 20m.   
Figure 5.  Comparison of phenotypic severity of HDQ150/150, HDQ315/+ and HDQ200/200 lines.  (A) Body 
weight normalized to wild type mice of same age and sex.  Black triangles represent HDQ150/150 mice (each 
point n= 13 to 22 except 80 weeks n=9). Gray circles represent HDQ315/+ mice (n= 13 to 29) and black squares 
represent 200/200 mice (n=3 to 7). (B) Rotarod performance normalized to wild type mice of same age.  Black 
triangles represent HDQ150/150 mice (each point n= 10 except 26 weeks n=31). Gray circles represent 
HDQ315/+ mice (n= 29-31) and black squares represent HDQ200/200 mice (n=3). (C)  In cage mouse activity 
normalized to wild type mice of same age.  Black triangles represent HDQ150/150 mice (each point n= 7-15 
except 26 weeks n=20). Gray circles represent HDQ315/+ mice (n= 29-31) and black squares represent 
HDQ200/200 mice (n=3). Asterisks show statistical significance compared to HDQ315/+ mice of most similar 
age by t-test (* p<0.05, ** p<0.01 and ***p<0.001).   Approximately equal numbers of male and female mice 
were used for each point. “a” indicates our previously published data adapted from (13).  Lines determined by 
method of least squares.  In each panel upper, middle and lower lines represent HDQ150/150, HDQ315/+ and 
HDQ200/200 mice respectively.      
Figure 6.  Expression correlates and discorrelates revealed by RNA sequencing analysis. (A-F) Ordering of 
lines based on increasing phenotypic severity.  Darker shading in arrows represents increased phenotypic 
severity.   Bars represent striatal FPKM values of all isoforms of each gene from left to right of WT (open), 
HDQ150/150 (black), HDQ315/+ (grey) and HDQ200/200 (black).  Definitions of correlate and discorrelate 
classes provided in Materials and Methods. (A-C) Examples of mRNAs with levels that correlate with 
phenotypic severity.  (D-F) Examples of mRNAs with levels that discorrelate with phenotypic severity.   (G-L) 
Ordering of lines based on increasing mutant gene dosage.  Numbers in arrows indicate mutant gene dosage.  
Bars represent striatal FPKM values of all isoforms of each gene from left to right of WT (open), HDQ315/+ 
(grey), HDQ200/200 (black) and HDQ150/150 (black).  Definition of correlate and discorrelate classes provided 
in Materials and Methods.  (G-I) Examples of mRNAs with levels that correlate with mutant gene dosage.  (J-
L) Examples of mRNAs with levels that discorrelate with mutant gene dosage.  Asterisks indicate p values 
calculated by Cuffdiff software based on dispersion model of variances (*p<0.05, **p<0.01, ***p<0.001).  
Table 3 contains a complete list of all correlates and discorrelates that have statistical support.   
Figure 7.   Levels of striatal mRNA from three commonly used markers of HD in mice.  Bars represent mean 
mRNA levels relative to WT as determined by QRTPCR using -actin as an internal control.   Darker shading in 
arrows represents increased phenotypic severity.  Open bars indicate WT, grey heterozygous and black 
homozygous for expanded CAG repeat allele. Number of mice is shown at the base of each bar.  RNA from 
each mouse analyzed individually to provide directly calculated statistics.  Error bars show the standard error of 
the mean, asterisks above brackets indicate statistical significance by ANOVA with Tukey-Kramer multiple 
comparisons test.  Asterisks directly above bars indicate significant difference from WT based on ANOVA with 
Dunnett Multiple comparisons test (*p<0.05, **p<0.01 and ***p<0.001).   
  
TABLES 
Table 1.  Offspring of heterozygous by heterozygous crosses 
CAG repeat length 
Offspring 50 100 150 200 250 315 
WT 26 64 192 79 67 18 
Heterozygote 39 101 317 163 109 35 
Homozygote 29 52 167  30*  1*  0* 
Total 94 217 676 272 177 53 
*Significant decrease from 1:2:1 Mendelian ratio (p<0.0005 Chi Square) 
 
Table 2. Concordance and enhanced discrimination supports use of ordering by phenotypic severity 
Allowed Variation (%) 0 3 6 9 12 15 18 21 
D
ec
re
as
in
g 
m
R
N
A
 le
ve
l 
WT +/-  > 150 +/-   7955 6680 5693 4917 4186 3679 3272 2948 
WT +/-  > 315 +/-  6609 5644 4874 4222 3728 3341 2894 2635 
WT +/-  > 200 +/-  9818 8924 7992 7039 6072 5170 4386 3694 
WT +/-  > 150 +/- ,  315 +/-  and 200 +/-          
Expecteda 214 139 92 60 39 26 17 12 
Observed 3306 2565 2026 1626 1318 1128 959 810 
Observed / Expected 15 18 22 27 34 43 56 68 
WT +/-  > 150 +/-  >  315 +/-  > 200 +/-  469 247 117 84 32 20 15 9 
Discrimination Ratiob 7 10 17 19 41 56 64 90 
In
cr
ea
si
ng
 m
R
N
A
 le
ve
l 
WT +/- < 150 +/-   7505 6215 4921 3861 3095 2544 2108 1813 
WT +/-  < 315 +/-  8874 7704 6423 5173 3981 3083 2479 1927 
WT +/-  < 200 +/-  5661 4927 4279 3761 3353 3002 2762 2531 
WT +/-  < 150 +/- ,  315 +/-  and 200 +/-          
Expected Concordantsa 156 98 56 31 17 10 6 4 
Observed Concordants 2252 1680 1214 945 748 616 526 379 
Observed/Expected 14 17 22 30 44 63 88 104 
WT +/-  < 150 +/- <  315 +/- < 200 +/-  272 137 83 60 44 31 27 23 
Discrimination Ratiob 8 12 15 16 17 20 20 17 
Shown is the number of genes out of 15,543 genes analyzed by RNA sequencing. All transcripts from a single gene 
combined and classified by relative FPKM between WT, 150 (HDQ150/150), 315 (HDQ315/+) and 200 
(HDQ200/200). aExpected is calculated as the product of the proportion of total altered genes of the  three mutant vs. 
WT comparisons times total number of genes.  bDiscrimination ratio is calculated as the observed concordants divided 
by the step-wise phenotypic correlates shown in the next row above. Bold numbers indicate calculated ratios.  
Statistical differences by Chi-square (p<0.0001) were found for all observed and expected concordants. 
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Alas2 chrX:150547416-150570622 3.86 2.73 1.16 0.89 NS ** ** * * NS 
 Hba-a1 chr11:32283671-32284493 99.48 82.94 35.18 25.72 NS *** *** *** *** NS 
 Hbb-bs chr7:103826522-103827928 211.5 200.8 86.12 55.43 NS *** *** *** *** NS 
 Hbb-b1 chr7:103812523-103813923 29.89 28.42 10.21 6.98 NS ** *** ** *** NS 
 Igfbp2 chr1:72824479-72852471 26.53 13.43 12.87 6.57 NS * *** NS * NS 
 Oprm1 chr10:6788600-7038209 0.09 0.14 0.16 0.80 ** NS NS *** NS ** 
 Sod3 chr5:52363803-52369738 8.14 7.31 3.73 3.27 NS * ** NS * NS 
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Abhd12b chr12:70154161-70183343 0.19 0.20 6.52 0.32 NS ** NS * NS * 
 Adam33 chr2:131050816-131063814 0.35 1.11 0.14 0.50 * NS NS * NS NS 
 Adcyap1 chr17:93199421-93205489 1.34 4.15 0.89 2.03 ** NS NS ** NS NS 
 Adh1 chr3:138277644-138290691 0.79 0.28 3.75 0.22 NS ** NS ** NS * 
 Agt chr8:124556586-124569707 5.59 3.96 12.65 4.09 NS ** NS *** NS * 
 Aldob chr4:49535976-49549483 0.58 1.25 4.64 0.57 NS *** NS ** NS ** 
 Apoc1 chr7:19689480-19692658 2.80 1.73 29.69 1.09 NS *** NS ** NS * 
 Arhgap25 chr6:87459384-87533235 1.31 2.64 1.19 1.63 * NS NS * NS NS 
 Bean1 chr8:104170512-104219097 0.98 2.90 1.82 1.40 ** NS NS NS * NS 
 Bex2 chrX:136066564-136068236 166.4 261.7 397.8 161.8 NS *** NS NS NS * 
 Bok chr1:93685693-93695762 9.81 18.67 25.33 8.60 NS *** NS NS * * 
 C1ql2 chr1:120340581-120343174 0.84 0.88 6.15 0.36 NS *** NS *** NS ** 
 Cabyr chr18:12741354-12755142 1.44 3.54 1.81 1.73 * NS NS NS * NS 
 Calb2 chr8:110142537-110168206 2.64 3.38 20.26 2.36 NS *** NS *** NS *** 
 Camk2n2 chr16:20611600-20646462 25.84 69.20 50.19 33.05 ** * NS NS * NS 
 Car3 chr3:14863537-14872373 0.62 0.83 5.61 0.36 NS ** NS ** NS * 
 Cbln1 chr8:87468852-87472592 1.78 2.79 6.02 1.47 NS ** NS * NS * 
 Ccdc135 chr8:95055102-95078141 3.61 0.42 1.58 0.88 *** * ** * NS NS 
 Ccdc136 chr6:29396427-29426995 12.24 23.01 33.47 13.60 NS *** NS NS NS * 
 Cck chr9:121489823-121495689 122.7 365.6 258.2 134.5 *** ** NS NS ** NS 
 Cckbr chr7:105425819-105436338 6.02 13.39 4.45 7.88 ** NS NS *** NS NS 
 Col9a3 chr2:180598221-180642691 9.71 4.00 8.20 2.97 ** NS ** * NS NS 
 Cox6a2 chr7:128173945-128206366 10.39 13.43 22.71 5.00 NS * NS NS * * 
 Cplx3 chr9:57599991-57606281 1.77 4.45 1.59 2.40 ** NS NS ** NS NS 
 Cpne6 chr14:55510310-55517446 18.85 27.98 50.27 20.78 NS *** NS NS NS * 
 Cpne7 chr8:123117373-123135185 3.94 5.12 17.78 3.75 NS *** NS *** NS *** 
 Crlf1 chr8:70493155-70504081 0.19 0.47 2.42 0.33 NS ** NS * NS * 
 Ctgf chr10:24595441-24598682 6.11 11.70 4.71 6.12 * NS NS ** NS NS 
 Cyp2e1 chr7:140763831-140774977 0.18 0.39 8.39 0.60 NS ** NS ** NS ** 
 Dkkl1 chr7:45207524-45212152 3.96 15.75 2.61 4.80 *** NS NS *** ** NS 
 Emx1 chr6:85187930-85206015 2.63 9.24 2.39 3.56 ** NS NS ** * NS 
 Epn3 chr11:94489598-94500270 1.05 0.25 1.71 0.29 ** NS * ** NS * 
 Fam183b chr11:58792801-58801960 3.60 1.03 6.29 1.60 * NS NS * NS NS 
 Fam81a chr9:70088500-70142424 14.41 30.47 14.91 21.89 ** NS NS *** NS NS 
 Fezf2 chr14:12341891-12345865 2.75 8.08 3.93 4.84 ** NS NS * NS NS 
 Fxyd7 chr7:31032722-31051499 25.31 59.52 35.54 26.57 ** NS NS NS * NS 
 Significant correlates and discorrelates (continued) 
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 Gbx2 chr1:89927961-89931176 0.58 0.42 4.60 0.36 NS *** NS ** NS * 
 Gfra2 chr14:70890082-70979838 3.88 9.89 3.40 6.12 *** NS NS *** NS NS 
 Gh chr11:106300260- 301896 2.29 0.74 2.76 0.70 * NS NS * NS NS 
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Gm11549 chr3:36515056-36525258 4.74 15.38 1.98 7.21 *** * NS *** * * 
 Gm14436 chr2:175470024-175483322 2.99 1.64 1.09 5.80 NS ** NS NS ** ** 
 Gm14446 chr19:34592887-34601968 0.42 1.19 0.32 0.66 * NS NS * NS NS 
 Gm3893 chr4:41889794-42462993 6.09 0.80 5.48 15.00 *** NS ** *** *** * 
 Grm2 chr9:106644503-106656109 1.78 6.00 4.86 2.87 ** ** NS NS * NS 
 Hkdc1 chr10:62383136-62422457 0.41 1.01 0.37 0.84 * NS NS * NS NS 
 Hs3st2 chr7:121392295-121502063 10.87 20.96 6.91 10.23 ** NS NS *** * NS 
 Il12a chr3:68690643-68698547 0.35 1.27 0.16 0.43 * NS NS * NS NS 
 Kcnab3 chr11:69326257-69333041 7.91 21.47 10.65 10.64 *** NS NS ** * NS 
 Kcng2 chr18:80294543-80364254 0.69 1.08 2.55 0.66 NS * NS NS NS * 
 Kcnq4 chr4:120696140-120747176 1.25 2.55 1.19 1.77 * NS NS * NS NS 
 Klk8 chr7:43797576-43803822 0.58 1.05 2.04 0.47 NS * NS NS NS * 
 Krt18 chr15:102028215-102032026 2.80 0.27 1.62 0.40 ** NS * * NS NS 
 Krt80 chr15:101348322-101370125 0.61 1.43 0.40 0.58 * NS NS * * NS 
 Lars2 chr9:123366939-123462664 167.1 335.0 164.6 152.3 * NS NS ** * NS 
 Lbp chr2:158306492-158332852 4.04 0.92 2.17 1.28 *** NS ** * NS NS 
 Lefty1 chr1:180935038-180938401 0.28 0.50 1.86 0.22 NS * NS * NS * 
 Lrrc17 chr5:21483846-21645605 12.02 11.11 23.92 4.55 NS ** ** ** ** *** 
 Lrrc23 chr6:124769862-124779720 3.89 1.56 4.59 2.02 * NS NS * NS NS 
 Mapk11 chr15:89142483-89149629 4.87 10.69 4.54 5.97 ** NS NS *** NS NS 
 Mid1 chrX:169685246-169991234 20.20 61.93 24.41 11.22 *** NS NS *** * NS 
 Mpped1 chr15:83780022-83858487 19.29 38.25 18.15 26.87 ** NS NS *** NS NS 
 Myl4 chr11:104502525-104595731 6.27 19.98 4.86 6.11 *** NS NS * NS NS 
 Ndn chr7:62348276-62349927 49.07 112.8 61.25 39.45 *** NS NS NS *** NS 
 Necab3 chr2:154544387-154559006 14.49 38.38 17.71 17.89 *** NS NS *** * NS 
 Neurod2 chr11:98325416-98329645 4.39 17.60 8.53 9.01 *** NS * ** * NS 
 Nov chr15:54745927-54753761 6.89 18.93 5.02 12.81 *** NS NS *** NS * 
 Nrn1 chr13:36725624-36734738 27.79 78.38 56.59 33.71 *** ** NS NS * NS 
 Ntn5 chr7:45677685-45694670 0.52 2.78 0.62 1.03 ** NS NS * NS NS 
 Ntsr1 chr2:180499975-180544979 0.44 1.08 0.43 0.93 * NS NS * NS NS 
 Odf3b chr15:89377345-89379474 3.72 1.27 4.69 2.12 * NS NS * NS NS 
 Olfm1 chr2:28193092-28230736 193.0 439.6 270.6 205.6 ** NS NS NS * NS 
 Olfm2 chr9:20667780-20746290 16.02 47.81 23.22 25.72 *** NS NS *** NS NS 
 Ovol2 chr2:144305175-144332080 0.79 2.84 0.44 1.08 ** NS NS ** NS NS 
 Pdzrn3 chr6:101149606-101377897 1.96 4.57 1.52 3.03 ** NS NS *** NS NS 
 Pnoc chr14:65400672-65425472 0.86 1.93 3.39 0.85 * ** NS NS NS * 
 Prkcd chr14:30595353-30626255 3.36 2.98 35.47 3.65 NS *** NS *** NS *** 
 Prss12 chr3:123446912-123506602 2.27 5.48 2.29 3.14 ** NS NS ** NS NS 
 Psrc1 chr3:108383803-108388231 0.71 2.49 0.92 0.98 ** NS NS * * NS 
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Rab37 chr11:115091430-115162522 1.28 1.36 7.63 1.13 NS *** NS *** NS ** 
 Ramp2 chr11:101246333-101248250 14.55 16.72 29.02 11.20 NS * NS NS NS * 
 Ramp3 chr11:6650147-6677475 5.74 5.10 22.35 4.11 NS *** NS *** NS ** 
 Resp18 chr1:75272201-75278593 23.71 45.55 39.27 22.10 ** NS NS NS * NS 
 Rgs16 chr1:153740352-153745468 1.77 2.57 10.70 2.02 NS *** NS *** NS ** 
 Rpl27 chr11:101442244-101445596 94.92 157.3 193.6 85.81 NS ** NS NS NS * 
 Rprm chr2:54084092-54085552 16.09 40.99 19.82 22.73 *** NS NS ** NS NS 
 Rsph1 chr17:31255019-31277356 5.46 2.01 5.92 2.25 * NS * * NS NS 
 Rtn4r chr16:18127705-18152408 7.88 24.79 13.06 11.27 *** NS NS NS * NS 
 Rtn4rl2 chr2:84871337-84887021 5.70 20.41 7.42 8.74 *** NS NS *** * NS 
 Satb2 chr1:56793980-56975196 3.61 8.59 1.72 6.13 *** * ** *** NS ** 
 Serpina3n chr12:104406707-104414329 2.59 4.08 7.68 2.94 NS ** NS NS NS * 
 Serpini1 chr3:75557499-75642523 33.49 68.20 32.62 55.81 ** NS NS *** NS NS 
 Shox2 chr3:66971571-66981771 0.45 0.55 10.11 0.40 NS *** NS *** NS ** 
 Slc17a7 chr7:45163920-45176139 56.96 199.1 71.75 106.3 *** NS NS *** NS NS 
 Slc26a10 chr10:127172340-127180645 5.99 2.74 6.51 2.69 * NS NS ** NS NS 
 Slc29a4 chr5:142702100-142722490 4.12 1.66 3.88 1.32 * NS ** * NS * 
 Slc30a3 chr5:31086105-31093527 4.99 22.17 7.66 8.83 *** NS NS *** ** NS 
 Slc39a4 chr15:76612382-76617216 0.80 0.23 0.82 0.36 * NS NS * NS NS 
 Sostdc1 chr12:36314168-36318452 7.60 0.44 1.69 0.55 *** ** ** * NS NS 
 Sstr1 chr12:58211803-58216036 1.45 4.38 1.11 3.74 ** NS * ** NS * 
 Sstr2 chr11:113618985-113626071 3.86 9.28 2.61 5.40 ** NS NS *** NS NS 
 Sstr3 chr15:78537014-78544345 1.11 3.11 1.53 1.81 ** NS NS * NS NS 
 Stac2 chr11:98036623-98053462 8.09 19.49 8.16 11.00 *** NS NS *** NS NS 
 Stx1a chr5:135023571-135051099 19.32 54.54 18.87 28.70 *** NS NS *** NS NS 
 Tbr1 chr2:61804452-61814113 9.97 27.52 6.13 18.43 *** NS NS *** NS ** 
 Tgm3 chr2:130006385-130050399 0.06 0.49 0.08 0.33 * NS NS * NS NS 
 Tnnt1 chr7:4504662-4515975 3.09 2.53 16.78 1.28 NS *** NS *** NS ** 
 Tpm2 chr4:43514711-43524487 8.59 3.73 9.00 2.94 ** NS ** ** NS * 
 Ttc9b chr7:27653923-27656207 46.52 97.31 47.70 36.33 ** NS NS *** ** NS 
 Ttr chr18:20665249-20674326 1520 63.89 304.8 49.22 *** *** *** *** NS *** 
 Tuba8 chr6:121210556-121226856 1.90 5.23 2.40 2.39 ** NS NS * * NS 
 Unnamed chr1:9548045-9631092 30.64 71.39 18.04 45.61 ** NS NS *** NS * 
 Unnamed chr2:32379100-32381915 54.32 108.8 63.39 39.55 ** NS NS NS ** NS 
 Unnamed chr18:85071618-85083540 18.48 2.04 10.54 2.83 ** NS ** * NS NS 
 Unnamed chr13:91368989-91388085 0.19 0.92 0.11 0.48 ** NS NS * NS NS 
 Unnamed chr3:68869585-68872163 2.57 5.45 1.43 3.02 * NS NS ** NS NS 
 Upb1 chr10:75406959-75440195 3.21 1.27 2.89 1.03 * NS NS * NS NS 
 Vip chr10:5639217-5647614 3.84 10.03 2.45 4.75 ** NS NS ** * NS 
 Wnt10a chr1:74792018-74804175 1.28 3.28 1.22 1.33 * NS NS * * NS 
 Wnt9a chr11:59306929-59333552 0.90 2.78 1.25 1.46 ** NS NS * NS NS 
 Zic2 chr14:122475383-122480328 4.93 5.15 13.61 4.03 NS *** NS *** NS ** 
 Zic4 chr9:91368873-91389348 0.70 0.51 2.28 0.56 NS ** NS * NS * 
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s Ccdc135 chr8:95055102-95078141 3.61 0.42 1.58 0.88 *** * ** * NS NS 
 Slc29a4 chr5:142702100-142722490 4.12 1.66 3.88 1.32 * NS ** * NS * 
 Sostdc1 chr12:36314168-36318452 7.60 0.44 1.69 0.55 *** ** ** * NS NS 
 Ttr chr18:20665249-20674326 1520 63.89 304.8 49.22 *** *** *** *** NS *** 
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Abhd12b chr12:70154161-70183343 0.19 0.20 6.52 0.32 NS ** NS * NS * 
 Adh1 chr3:138277644-138290691 0.79 0.28 3.75 0.22 NS ** NS ** NS * 
 Agt chr8:124556586-124569707 5.59 3.96 12.65 4.09 NS ** NS *** NS * 
 Alas2 chrX:150547416-150570622 3.86 2.73 1.16 0.89 NS ** ** * * NS 
 Aldob chr4:49535976-49549483 0.58 1.25 4.64 0.57 NS *** NS ** NS ** 
 Apoa1 chr9:46228629-46230466 0.39 0.24 25.59 0.08 NS ** NS * NS NS 
 Apoa2 chr1:171225053-171226379 0.65 1.10 39.35 0.40 NS ** NS *** NS NS 
 Apoc1 chr7:19689480-19692658 2.80 1.73 29.69 1.09 NS *** NS ** NS * 
 Apoc3 chr9:46233050-46235297 1.13 0.59 10.76 0.08 NS ** NS * NS NS 
 Beta-s chr7:103826522-103827928 211.5 200.8 86.12 55.43 NS *** *** *** *** NS 
 Bex2 chrX:136066564-136068236 166.4 261.7 397.8 161.8 NS *** NS NS NS * 
 Bok chr1:93685693-93695762 9.81 18.67 25.33 8.60 NS *** NS NS * * 
 Btg2 chr1:134074864-134079155 7.13 6.21 2.90 3.82 NS ** NS * NS NS 
 C1ql2 chr1:120340581-120343174 0.84 0.88 6.15 0.36 NS *** NS *** NS ** 
 Calb2 chr8:110142537-110168206 2.64 3.38 20.26 2.36 NS *** NS *** NS *** 
 Camk2n2 chr16:20611600-20646462 25.84 69.20 50.19 33.05 ** * NS NS * NS 
 Car3 chr3:14863537-14872373 0.62 0.83 5.61 0.36 NS ** NS ** NS * 
 Cbln1 chr8:87468852-87472592 1.78 2.79 6.02 1.47 NS ** NS * NS * 
 Ccdc136 chr6:29396427-29426995 12.24 23.01 33.47 13.60 NS *** NS NS NS * 
 Cox6a2 chr7:128173945-128206366 10.39 13.43 22.71 5.00 NS * NS NS * * 
 Cpne6 chr14:55510310-55517446 18.85 27.98 50.27 20.78 NS *** NS NS NS * 
 Cpne7 chr8:123117373-123135185 3.94 5.12 17.78 3.75 NS *** NS *** NS *** 
 Crlf1 chr8:70493155-70504081 0.19 0.47 2.42 0.33 NS ** NS * NS * 
 Cyp2e1 chr7:140763831-140774977 0.18 0.39 8.39 0.60 NS ** NS ** NS ** 
 Cyp2f2 chr7:27119954-27133660 0.10 0.13 1.29 0.06 NS * NS * NS NS 
 Epn3 chr11:94489598-94500270 1.05 0.25 1.71 0.29 ** NS * ** NS * 
 Gbx2 chr1:89927961-89931176 0.58 0.42 4.60 0.36 NS *** NS ** NS * 
 Gm11549 chr3:36515056-36525258 4.74 15.38 1.98 7.21 *** * NS *** * * 
 Gm14436 chr2:175470024-175483322 2.99 1.64 1.09 5.80 NS ** NS NS ** ** 
 Gm3893 chr4:41889794-42462993 6.09 0.80 5.48 15.00 *** NS ** *** *** * 
 Gpr4 chr7:19212537-19224176 1.24 1.62 3.41 1.68 NS * NS * NS NS 
 Hba-a1 chr11:32283671-32284493 99.48 82.94 35.18 25.72 NS *** *** *** *** NS 
 Hba-a2 chr11:32296488-32297310 0.04 12.53 0.00 0.00 NS ** ** ** *** NS 
 Hbb-b1 chr7:103812523-103813923 29.89 28.42 10.21 6.98 NS ** *** ** *** NS 
 Hp chr8:109575127-109579172 0.42 0.23 3.37 0.10 NS ** NS ** NS NS 
 Hpx chr7:105591610-105600116 0.29 0.34 5.30 0.10 NS ** NS ** NS NS 
 Kcng2 chr18:80294543-80364254 0.69 1.08 2.55 0.66 NS * NS NS NS * 
 Klk8 chr7:43797576-43803822 0.58 1.05 2.04 0.47 NS * NS NS NS * 
 Lef1 chr3:131110296-131224357 3.55 3.36 7.61 3.10 NS * NS ** NS NS 
 Significant correlates and discorrelates (continued)
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Lefty1 chr1:180935038-180938401 0.28 0.50 1.86 0.22 NS * NS * NS * 
 Lrrc17 chr5:21483846-21645605 12.02 11.11 23.92 4.55 NS ** ** *** ** *** 
 Nr4a1 chr15:101266845- 274794 58.45 40.20 19.74 32.31 NS *** NS *** NS NS 
 Ntf3 chr6:126101411-126166744 0.20 0.37 1.57 0.25 NS * NS * NS NS 
 Oprm1 chr10:6788600-7038209 0.09 0.14 0.16 0.80 ** NS NS *** NS ** 
 Pkp2 chr16:16213330-16272712 2.15 2.10 5.37 2.20 NS ** NS ** NS NS 
 Plekhd1 chr12:80692600-80724216 1.05 0.89 2.28 0.96 NS * NS * NS NS 
 Pnoc chr14:65400672-65425472 0.86 1.93 3.39 0.85 * ** NS NS NS * 
 Prkcd chr14:30595353-30626255 3.36 2.98 35.47 3.65 NS *** NS *** NS *** 
 Rab37 chr11:115091430- 162522 1.28 1.36 7.63 1.13 NS *** NS *** NS ** 
 Ramp2 chr11:101246333-248250 14.55 16.72 29.02 11.20 NS * NS NS NS * 
 Ramp3 chr11:6650147-6677475 5.74 5.10 22.35 4.11 NS *** NS *** NS ** 
 Rgs16 chr1:153740352-153745468 1.77 2.57 10.70 2.02 NS *** NS *** NS ** 
 Rpl27 chr11:101442244- 445596 94.92 157.3 193.6 85.81 NS ** NS NS NS * 
 Satb2 chr1:56793980-56975196 3.61 8.59 1.72 6.13 *** * ** *** NS ** 
 Serpina3n chr12:104406707-414329 2.59 4.08 7.68 2.94 NS ** NS NS NS * 
 Shox2 chr3:66971571-66981771 0.45 0.55 10.11 0.40 NS *** NS *** NS ** 
 Slco2a1 chr9:103008488-103087959 0.16 0.15 0.83 0.18 NS * NS * NS NS 
 Snx31 chr15:36504061-36555572 0.18 0.11 0.94 0.26 NS * NS * NS NS 
 Sod3 chr5:52363803-52369738 8.14 7.31 3.73 3.27 NS * ** NS * NS 
 Spink8 chr9:109816625-109826754 0.61 0.67 4.34 0.29 NS * NS * NS NS 
 Tdo2 chr3:81958413-81975728 0.31 0.15 1.64 0.27 NS * NS * NS NS 
 Tnnt1 chr7:4504662-4515975 3.09 2.53 16.78 1.28 NS *** NS *** NS ** 
 Wnt3 chr11:103774174- 818021 1.10 1.13 2.67 1.18 NS * NS * NS NS 
 Zic2 chr14:122475383-480328 4.93 5.15 13.61 4.03 NS *** NS *** NS ** 
 Zic4 chr9:91368873-91389348 0.70 0.51 2.28 0.56 NS ** NS * NS *  
 Classes defined in Materials and Methods.  Asterisks indicate statistical significance calculated by Cuffdiff 
 (* p<0.05, **p<0.01, ***p=<0.001, NS = Not Significant).
  
Table 4. Transcript level classification by ordering across allelic series 
 Allowed variation (%) 0 3 6 9 12 15 18 21 
 
Order: 
 
Phenotypic 
severity 
No effect 0 1 4 10 17 24 31 38 
 Partial correlate 0 9 17 23 28 30 30 28 
 Step-wise correlate 5 2 1 1 0.5 0.3 0.3 0.2 
 Discorrelate 95 88 77 66 55 46 39 34 
 
Order: 
 
Mutant gene 
dosage 
No effect 0 1 3 8 14 21 28 35 
 Partial correlate 14 25 34 40 44 45 44 41 
 Step-wise correlate 3 1.5 0.8 0.5 0.4 0.2 0.2 0.1 
 Discorrelate 83 73 62 51 41 34 28 24 
Shown are the percentages of 15,543 genes analyzed by RNA sequencing. All transcripts from a 
single gene combined and classified by relative FPKM between WT, HDQ150/150, HDQ315/+ and 
HDQ200/200 mice. Class definitions are described in Materials and Methods. For all >21%, no 
effect category increase at the expense of correlates and discorrelates. 
 
Table 5. Transcript level changes with processing and/or degradation rate alteration 
 Allowed variation (%) 5 10 15 20 30 40 50 60 70 80 90 
 WT vs. HDQ150/150            
 Minor isoforms changed in level 6215 5161 4272 3475 2366 1692 1253 973 811 726 677 
 P/DWT  ≠ P/Dmut 80% 68% 61% 56% 52% 54% 61% 72% 81% 87% 83% 
 WT vs. HDQ315/+            
 Minor isoforms changed in level 6470 5532 4620 3843 2661 1864 1338 1016 814 716 649 
 P/DWT  ≠ P/Dmut 83% 73% 68% 62% 55% 53% 58% 67% 78% 84% 84% 
 WT vs. HDQ200/00            
 Minor isoforms changed in level 6478 5535 4662 3882 2714 1930 1422 1100 894 768 676 
 P/DWT  ≠ P/Dmut 82% 71% 64% 59% 53% 52% 56% 63% 73% 81% 84% 
Table represents 7433 minor isoforms from 5950 genes.  Major isoforms are not included in this table since they 
are used as a denominator in calculating P/D ratios, the processing-degradation ratio calculated as described in 
text. Minor isoforms changed in level do not have overlapping values when variation is added to the lesser of the 
two FPKM values (FPKMWT and FPKMmut) and subtracted from the greater. Variation was used to calculate a 
range for each P/D ratio with a maximum (FPKMminor + minor)/(FPKMmajor - major) and a minimum  
(FPKMminor - minor)/FPKMmajor+major). Overlapping ranges indicate that P/DWT = P/Dmut.  Percentages indicate 
the number of isoforms changed in level with non-equivalent P/D ratios divided by the total number of isoforms 
changed in level.  P/D ratios tend to be equivalent for transcripts that are not changed in levels between lines (Chi-
square p<0.0001 for comparisons between unchanged group and every changed group presented in this table).  
 
  
  
Table 6.  Classification for genes with transcript levels previously shown to be altered in HD 
 Allowed variation (%) 0 3 6 9 12 15 18 21 
 
Order: 
 
Phenotypic 
severity 
No effect 0 0 2 5 11 23 33 41 
 Partial correlate 0 10 20 32 34 41 41 44 
 Step-wise correlate 4 3 2 0 0 0 0 0 
 Discorrelate 96 87 76 63 55 36 26 15 
 
Order: 
 
Mutant gene 
dosage 
No effect 0 0 2 4 11 17 26 36 
 Partial correlate 32 49 54 67 65 67 63 57 
 Step-wise correlate 6 3 3 1 1 0 0 0 
 Discorrelate 62 48 41 28 23 16 11 7 
Shown are the percentages in each class of 100 genes with transcript levels previously shown to be 
altered in HD (From Table 3 of Seredenina and Luthi-Carter, 2011, (21)). Class definitions are 
described in Materials and Methods.  All transcripts from a single gene combined and classified by 
relative FPKM between WT, HDQ150/150, HDQ315/+ and HDQ200/200 mice. For all >21%, no 
effect category increase at the expense of correlates and discorrelates. 
ABBREVIATIONS 
ANOVA analysis of variance, a standard statistical test  
bp is base pair 
BSA is bovine serum albumin 
cDNA is complementary deoxyribonucleic acid 
CAG a sequence of DNA containing cytosine adenine guanine, expanded repeats of which can cause diseases 
Cy3 is Cyanine 3, a green fluorescent dye  
D1 is the mouse dopamine receptor D1 
D2 is the mouse dopamine receptor D2 
DNA is deoxyribonucleic acid 
Gene designations (which should not be italicized as they refer to a transcript from that gene) are as provided by 
University of California Santa Cruze mm10 mouse genome annotation 
HDQ150, HDQ200, HDQ315 are alleles of the mouse HD locus with 150, 200 and 315 CAGs respectively 
HDQ150/150, HDQ200/200 are homozygotes for the HDQ150 and HDQ200 alleles respectively 
HDQ315/+ is a heterozygote for the HDQ315 allele and a wild type HD allele 
mRNA is messenger ribonucleic acid 
MW is molecular weight 
PCR is polymerase chain reaction 
polyQ is poly glutamine 
Q is glutamine 
qPCR is quantitative real-time polymerase chain reaction 
QRTPCR is quatitative reverse transcription real-time polymerase chain reaction 
R6/2 is a mouse line transgenic for an HD mutation from which an allelic series with different length CAG 
repeats was derived 
R6/2-Q150 a mouse line transngenic for an HD mutation with 150 CAGs. 
RNA is ribonucleic acid 
SNP is single nucleotide polymorphism 
WT is wild type 
Common abbreviations 
cm is centimeter 
UV is ultraviolet  
min is minute 
nm is nanometer  
sec is second 
s is seconds 
m is meter 
m is micrometer 
km is kilometer 
g is gram 
mg is milligram 
mm is millimeter 
Mathematical abbreviations defined in text 
KT is the rate of production of full length primary transcript in FPKM produced per second 
KD is the rate of transcript degradation per second 
KD,major is the rate of transcript degradation per second of the most abundant isoform from a single gene 
KD,minor is the rate of transcript degradation per second of any isoform other than the most abundant 
Pi is the proportion of the mRNA from a single gene that is processed to a particular isoform, i.  
Pmajor is the proportion of the mRNA from a single gene that is processed to the most abundant isoform 
Pminor is the proportion of the mRNA from a single gene that is processed to any isoform other than the most 
abundant 
FPKM fragments per kilobase of transcript per million fragments mapped, a measured value. 
FPKMi fragments per kilobase of transcript per million fragments mapped for a particular isoform, i. 
FPKMmajor fragments per kilobase of transcript per million fragments mapped for the most abundant isoform 
FPKMminor fragments per kilobase of transcript per million fragments mapped for any isoform except most 
abundant 
P/D ratio is the processing degradation ratio.   
is the allowed variation a variable describing a percentage of an FPKM value. 
major is the product of the allowed variation and the FPKM value of the most abundant transcript isoform  
major is the product of the allowed variation and the FPKM value for any isoform other than the most abundant  








